The Challenges of High-Cost Therapies in Employee Benefit Programs | PR Newswire [Video]

, /PRNewswire/ — The Integrated Benefits Institute (IBI) today unveiled a report on employers’ challenges in incorporating high-cost therapies, such as cell and gene therapies (CGTs) and GLP-1 medications, into their employee benefit plans.

The report reveals that 33% of employers currently include CGTs in their benefit plans, with 36% actively evaluating CGT strategies. Notably, 58% of non-adopters plan to implement CGT benefits in the next 24 months. Most (90%) employers link CGT benefits to enhanced employee productivity and recognize CGTs’ lifesaving potential to avert costly long-term interventions (91%).

Key findings indicate that stop-loss (SL) coverage strongly predicts CGT benefit adoption. Organizations with high revenue and SL coverage boast a 72% adoption rate, while small organizations without SL coverage have a 28% adoption rate.

Dr. Sera-Leigh Ghouralal, Senior Researcher at IBI, stated, “There is a strong relationship between organizational readiness and the adoption of these innovative therapies. Organizations with robust stop-loss coverage …